Unaudited Interim Results

Emmerson PLC is pleased to announce its Unaudited Interim Results for the six month period ended 30 June 2026 and to provide a brief update on activities.

Highlights

In March, the Company raised a total of US$1.0 million, through a £750,000 placing and subscription, alongside gross proceeds of £100,000 through a WRAP Retail Offer (together, the “Fundraise”).

On 27 March the Company submitted its Memorial in relation to the arbitration process, outlining the Company's case in full, including legal arguments and supporting evidence. This included a claim for damages amounting to US$1.215bn net of local taxes and including interest.

Emmerson’s United Kingdom patent application concerning the Khemisset Multi-mineral Process (“KMP”) was successfully granted during June.

In May, Morocco applied to have the jurisdictional element of the case bifurcated, which, following a hearing in June, was denied by the tribunal.

Legal matters

At the end of March, the Company advised that its legal representatives, Boies Schiller Flexner LLP, had submitted its Memorial in accordance with the timetable set out by the arbitration panel.

The Memorial outlined the Company’s case in full, including legal arguments and supporting evidence. This included a claim for damages amounting to US$1.215bn net of local taxes and including interest.

The Company was at an advanced stage of development at the time of Morocco’s breaches of its obligations under the United Kingdom-Morocco Bilateral Investment Treaty and has employed expert quantum consultants to determine the claim value. This rigorous process was based on studies published by the Company including discounted cash flow analyses.

Following the Memorial being successfully submitted on time, the arbitration moved to the next phase where Morocco will have an opportunity to respond.

In May 2026, Morocco applied to the Tribunal to have certain jurisdictional objections bifurcated, i.e., addressed by the Tribunal in a separate, preliminary phase, before evaluating the merits of the Claimants’ claims in the arbitration. The Claimants opposed that application and the Tribunal held a hearing on 19 June 2026, during which the parties made oral submissions regarding whether the Tribunal should grant Morocco’s application.

On 17 July 2026, the Tribunal issued its decision on bifurcation. It rejected Morocco’s application. This means that the Tribunal will address Morocco’s objections at the same time as it analyses the merits of the case.

The timing of the next steps in the process up to and including the hearing to address both the jurisdictional element and the merits was confirmed by the tribunal during August with the key dates being:

 Morocco’s Counter-Memorial, in which it will set out in full its defences and jurisdictional objections to the claims and provide its supporting evidence, will be due in January 2027;

 Emmerson’s Reply to the Counter-Memorial, responding to Morocco’s Counter-Memorial and providing further supporting evidence, will be due in October 2027;

 Morocco`s Rejoinder, responding to our Reply and providing further evidence, will then be due in January 2028.

 The hearing will take place from 17-26 July 2028, during which the parties will make submissions and witnesses and experts will be cross-examined before the Tribunal.

Other

In March, the Company completed a successful £750,000 placing and subscription, alongside raising gross proceeds of £100,000 through a WRAP Retail Offer (together, the “Fundraise”). The net proceeds of the Fundraise will be used to cover the costs of remediation of the site of the Mine de Centre and to pay invoices for completed engineering work and supplementary consultancy work in preparation of the legal case. The Fundraise also strengthens the Company’s financial position while navigating the arbitration process.

Emmerson’s patent application concerning the Khemisset Multi-mineral Process was successfully granted patent status in June. The United Kingdom Intellectual Property Office (UKIPO) confirmed that Emmerson’s patent application titled Processing of Evaporite Minerals (Application No. 2315003.0) had been granted patent status (Patent No. 2634094). This patent provides IP protection for the core KMP process and its optimised derivative products.

For further information, please visit www.emmersonplc.com, follow us on X (@emmerson_plc), or contact:

Condensed Consolidated Statement of Financial Position at 30 June 2026

Condensed Consolidated Statement of Changes in Equity for the six months ended 30 June 2026

Condensed Consolidated Statement of Cash Flows for the six months ended 30 June 2026

Notes to the Condensed Consolidated Financial Statements for the six months ended 30 June 2026

General information

Emmerson PLC is a company incorporated and domiciled in the Isle of Man, whose shares have since 27 April 2021 been listed on AIM.

The principal activities of the Group are the pursuance of a dispute with the Moroccan Government regarding the Khemisset Potash project (the “Project”), and the development of the Company's proprietary potash processing technology known as KMP. In previous years, the principal activity was the development of the Khemisset Potash project, however the rejection of the Company's environmental permit application in October 2024, resulting in the total expropriation of the Project, necessitated a change in strategy.

Basis of preparation

2.1 General

The Condensed Consolidated Financial Statements have been prepared in accordance with the valuation and recognition principles of UK-adopted International Accounting Standards. The Condensed Consolidated Financial Statements for the six months ended 30 June 2026 are unaudited and have not been reviewed by the Group’s auditor, and do not include all of the information required for full annual financial statements.

They should be read in conjunction with the Company’s annual financial statements for the year ended 31 December 2025. The principal accounting policies applied in the preparation of the Condensed Consolidated Financial Statements are unchanged from those disclosed in those statements. These policies have been consistently applied to each of the periods presented.

The financial information of the Group is presented in US Dollars, which is also the functional currency of the parent Company and has been prepared under the historical cost convention. The individual financial statements of each of the Company’s wholly owned subsidiaries are prepared in the currency of the primary economic environment in which it operates (its functional currency).

2.2 Basis of consolidation

The Consolidated Financial Statements comprise the financial statements of the Company, Moroccan Salts Limited (“MSL”), Potasse de Khemisset SA, Mines de Centre SARL, and Khemisset UK Ltd (“KUL”).

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtains control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

The contractual arrangement with the other vote holders of the investee;

Rights arising from other contractual arrangements; and

The Group's voting rights and potential voting rights.

All intra-group balances, transactions, income and expenses and profits and losses resulting from intra-group transactions that are recognised in assets, are eliminated in full.

All the Group’s companies have 31 December as their year-end. Consolidated financial statements are prepared using uniform accounting policies for like transactions.

2.3 Functional and presentational currency

The financial information of the Group is presented in US Dollars, which is also the functional currency of the parent Company, and has been prepared under the historical cost convention. The individual financial statements of each of the Company’s wholly owned subsidiaries are prepared in the currency of the primary economic environment in which it operates (its functional currency).

2.4 Going concern

As at 9 September 2026 the Group had cash and cash equivalents of US$891k. On 2 January 2025, the Company signed a Capital Provision Agreement ("CPA") with a specialist litigation funding firm to provide up to US$11.0 million in both litigation finance capital and working capital for the Company.

The Company has prepared a cashflow forecast to December 2027 setting out the expected financial commitments related to the running of the Group in its reduced scale, and the legal and other advisory expenses related to the ongoing dispute with the Moroccan government. The Company will not commit to further material financial obligations for at least the 12 months from the date of this report in order to protect its Going Concern position.

Based on a review of the cashflow forecast, the Board is satisfied that the existing cash and funding facility are more than sufficient to meet the Company’s outgoings for at least 12 months from the date of this report, and therefore believe the Going Concern basis is appropriate for the preparation of the financial statements.

Administrative fee and other expenses

Litigation funding

On 2 January 2025, the Company announced that it had signed a Capital Provision Agreement ("CPA") with a specialist litigation funding firm to provide up to US$11.0 million in both litigation finance capital and working capital for the Company (the "Funding"). Funds advanced under the CPA can be used to settle legal fees connected with the case, as well as for general working capital purposes, subject to approvals.

Funds advanced are non-recourse and are not repayable in the event of the legal case being lost. If the case has a successful outcome, the litigation funding firm will receive capital a capital entitlement based on multiples of the amounts advanced, or a percentage of the total settlement, depending on the timing and quantum of the settlement.

Because the funds advanced confer present benefits whose value can be quantified, these advances are recognised as Other Income. The balance of entitlements under the CPA will be recognised upon settlement of the legal case, as a reduction against the final award.

During the period, the Company incurred litigation expenses of US$2,341k (31 Dec 2025: US$1,809). Amounts settled through advances under the CPA totalled US$1,635k (31 Dec 2025: US$1,317k) and have been recognised as Other Income. The amounts settled in the period included both litigation expenses incurred during the period and litigation payables recognised at 31 December 2025. At 30 June 2026, unpaid litigation costs of US$1,252k (31 Dec 2025: US$492k) were included within current liabilities.

Current and Non-current liabilities

In addition to US$1,252k (31 Dec 2025: US$492k) of unpaid litigation costs (see note 4), current liabilities include an amount of US$188k (31 Dec 2025: US$188) relating to the provision of the basic engineering package for the Company’s Khemisset Potash Project.

Earnings per share

The calculation of the basic and diluted earnings per share is based on the following data:

Number of shares

Weighted average number of ordinary shares for the purpose of basic and diluted earnings per share

Related party transactions

Directors’ consultancy fees

Graham Clarke is a Director of the Company and also provides consulting services to the Company. During the period, Graham Clarke received fees of US$201k (H1 2025: US$196k). The amount outstanding as at the period end was US$ nil (31 Dec 2025: US$ nil).

Hayden Locke is a Director of the Company and also provides consulting services to the Company. During the period, Hayden Locke received fees of US$40k (H1 2025: US$40k). The amount outstanding as at the period end was US$6k (31 Dec 2025: US$ nil).

Post-balance sheet events

There were no post-balance sheet events.